NYXOAH SA - ORDINARY S

Nyxoah BETTER SLEEP Trial Reaches its Primary Endpoints

07 июн 2021 01:00:00 Источник Nasdaq GlobeNewswire

Publication relating to a transparency notification

26 май 2021 13:25:33 Источник Nasdaq GlobeNewswire

Invitation to attend the annual shareholders’ meeting of the Company to be held on 9 June 2021

07 май 2021 01:00:00 Источник Nasdaq GlobeNewswire

Nyxoah Announces Submission of Draft Registration Statement For Proposed Public Listing in the United States

19 апр 2021 01:02:35 Источник Nasdaq GlobeNewswire

Nyxoah Reports Full Year 2020 Results

09 апр 2021 00:57:16 Источник Nasdaq GlobeNewswire

Nyxoah to Delay Full Year 2020 Earnings Release Until April 9, 2021  

02 апр 2021 01:02:48 Источник Nasdaq GlobeNewswire

Nyxoah announces the publication of first positive clinical data in an OSA patient suffering from Complete Concentric Collapse (CCC)

03 мар 2021 00:58:24 Источник Nasdaq GlobeNewswire

Information on the total number of voting rights and shares

25 фев 2021 12:00:28 Источник Nasdaq GlobeNewswire

Nyxoah to present at the Oppenheimer 31st Annual Healthcare Conference

24 фев 2021 01:01:35 Источник Nasdaq GlobeNewswire

Nyxoah receives FDA approval for full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA)

09 фев 2021 01:00:13 Источник Nasdaq GlobeNewswire

Nyxoah and Vanderbilt University enter exclusive licensing agreement regarding next generation neurostimulation technologies to treat Obstructive Sleep Apnea (OSA)

02 фев 2021 00:56:05 Источник Nasdaq GlobeNewswire

Nyxoah announces full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA)

26 янв 2021 01:02:09 Источник Nasdaq GlobeNewswire

First US patient implanted in the DREAM pivotal IDE study, with the Genio® system for the treatment of Obstructive Sleep Apnea (OSA)

05 янв 2021 01:39:42 Источник Nasdaq GlobeNewswire